Cooper Companies Q3 Results Up, Cuts FY26 View, Retains CooperSurgical, Expands Buyback; Shares Down
CooperCompanies (COO) reported Q3 earnings up but cut its FY26 outlook, citing U.S. channel inventory reductions at CooperVision. The company will retain CooperSurgical and expand its share buyback program to $3B. Shares fell 14.07% in overnight trading. Q4 guidance includes adjusted EPS of $1.05-$1.09 and revenue of $1.057B-$1.080B. FY26 outlook revised to EPS of $4.51-$4.55 and revenue of $4.229B-$4.252B.
How this was made
The 30-second read
Why it matters
The earnings beat was offset by a significant guidance cut, leading to a sharp share decline. The buyback may provide a floor for the stock.
Market read
The news directly impacts COO stock and may influence sentiment in the broader medical device sector.
What to watch
Inventory reductions at CooperVision may improve margins in Q4 despite short-term revenue pressure.
Background
Cooper Companies released its Q3 results, updated FY26 guidance, and announced a larger share repurchase program.
Ticker impact
Cooper Companies reported Q3 earnings, trimmed FY26 outlook and announced a $3B buyback, causing a 14% share drop.
Potential further decline in near-term as investors digest lower guidance, with possible rebound if buyback activity materializes.
Guidance reduction and large share price drop indicate immediate bearish pressure, while the expanded buyback could limit downside over the longer term.
Market effects
Medical device sector may face pressure as peers' guidance cuts raise concerns about demand.
US healthcare stocks could see modest pullback following the earnings miss.
Limited to US-listed medical device companies and related supply chains.
Counterpoint
Buyback expansion suggests management confidence; long positions could be considered at lower levels.
Key entities
- CompanyCooper Companies, Inc.
Medical device manufacturer reporting earnings and guidance.
